1/13/2026

Moxifloxacin Injection

Products Affected - Description

- Moxifloxacin injection, Fresenius Kabi, 400 mg/250 mL, premixed bag, 12 count, NDC 63323-0850-74 - discontinued
- Moxifloxacin injection, Mylan Institutional (Viatris), 400 mg/250 mL, premixed bag, 12 count, NDC 67457-0323-25

Reason for the Shortage

- Fresenius Kabi recently discontinued moxifloxacin injection.
- Viatris did not provide a reason for the shortage. They are sole suppliers of moxifloxacin injection.

Available Products

- There are no presentations available

Estimated Resupply Dates

- Viatris has moxifloxacin 400 mg/250 mL premixed bags on back order and the company estimates a release date of late-November 2026.

Updated

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.